Sarepta Therapeutics Inc (SRPT): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Sarepta Therapeutics ( SRPT) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.6%. By the end of trading, Sarepta Therapeutics rose 74 cents (2.9%) to $26.02 on light volume. Throughout the day, 1.3 million shares of Sarepta Therapeutics exchanged hands as compared to its average daily volume of 2.7 million shares. The stock ranged in a price between $25.25-$27.25 after having opened the day at $25.50 as compared to the previous trading day's close of $25.28. Other companies within the Drugs industry that increased today were: AcelRx Pharmaceuticals ( ACRX), up 22.8%, Synergy Pharmaceuticals ( SGYP), up 12.3%, Palatin Technologies ( PTN), up 11.5%, and Supernus Pharmaceuticals ( SUPN), up 9.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of serious and life-threatening rare and infectious diseases. Sarepta Therapeutics has a market cap of $683.7 million and is part of the health care sector. The company has a P/E ratio of -10, below the S&P 500 P/E ratio of 17.7. Shares are up 3293.3% year to date as of the close of trading on Wednesday. Currently there are five analysts that rate Sarepta Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Sarepta Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and disappointing return on equity.

On the negative front, Tranzyme ( TZYM), down 76.1%, Natural Alternatives International ( NAII), down 22.9%, AspenBio Pharma ( APPY), down 14.6%, and Galena Biopharma ( GALE), down 11.1%, were all laggards within the drugs industry with Bristol-Myers Squibb Company ( BMY) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.
null

If you liked this article you might like

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

Sound Familiar? Dovish Fed Talk Induces Stock Reversal

With an Eye on Biotech, Here's Today's Trading Thesis

With an Eye on Biotech, Here's Today's Trading Thesis

Focused on Two Sectors

Focused on Two Sectors

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

Solid Biosciences Soars 41% in IPO Despite Late Disclosure of FDA Letter

In This Booming Stock Market, Think Like a Programmer Not a Critic

In This Booming Stock Market, Think Like a Programmer Not a Critic